Galle P et al. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology front wo randomised, placebo-controlled phase 3 studies (REACH-2 and REACH). (Abstract GS-09)
Indices om cirrose uit te sluiten bij chronische hepatitis B verder geoptimaliseerd
jul 2019 | Hepatitis, Virale infecties